首页> 外文期刊>Biotechnic and Histochemistry >The role of CXC chemokine ligand 4/CXC chemokine receptor 3-B in breast cancer progression
【24h】

The role of CXC chemokine ligand 4/CXC chemokine receptor 3-B in breast cancer progression

机译:CXC趋化因子配体4 / CXC趋化因子受体3-B在乳腺癌进展中的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Chemokines and their receptors participate in the development of cancers by enhancing tumor cell proliferation, angiogenesis, invasion, metastasis and penetration of tumor immune cells. It remains unclear whether CXC chemokine ligand 4 (CXCL4)/CXC chemokine receptor 3-B (CXCR3-B) can be used as an independent molecular marker for establishing prognosis for breast cancer patients. We evaluated CXCL4 and CXCR3-B expression in 114 breast cancer tissues and 30 matched noncancerous tissues using immunohistochemistry and western blot, and determined the correlation between their expression and clinicopathologic findings. We observed that breast cancer tissues express CXCL4 strongly and CXCR3-B weakly compared to noncancerous tissues. Strong CXCL4 expression was detected in 94.7% and weak CXCR3-B expression was detected in 78.9% of the tissues. Therefore, CXCL4/CXCR3-B might play a crucial role in breast cancer progression. We found no significant correlation between CXCL4 and age, tumor stage, tumor grade or TNM stage. CXCR3-B was associated significantly with tumor grade. Moreover, the Chi-square test of association showed that the expression of CXCL4/CXCR3-B might be an independent prognostic marker for breast cancer. Therefore, we suggest that CXCR3-B is an indicator of poor prognosis and may also be a chemotherapeutic target.
机译:趋化因子及其受体通过提高肿瘤细胞增殖,血管生成,侵袭,转移和肿瘤免疫细胞的渗透来参与癌症的发展。仍然不清楚CXC趋化因子配体4(CXCL4)/ CXC趋化因子受体3-B(CXCR3-B)可用作为乳腺癌患者建立预后的独立分子标记。我们在114个乳腺癌组织中评估了CXCL4和CXCR3-B表达,并使用免疫组化和Western印迹进行了30种匹配的非癌组织,并确定了它们的表达和临床病理学发现之间的相关性。我们观察到乳腺癌组织与非癌组织相比,乳腺癌组织强烈和CXCR3-B弱。在94.7%中检测到强烈的CXCl4表达,并在78.9%的组织中检测到弱CXCR3-B表达。因此,CXCL4 / CXCR3-B可能在乳腺癌进展中发挥至关重要的作用。我们发现CXCL4和年龄,肿瘤阶段,肿瘤等级或TNM阶段之间没有显着相关性。 CXCR3-B与肿瘤级显着相关。此外,关联的Chi-Square试验表明CXCL4 / CXCR3-B的表达可能是乳腺癌的独立预后标志物。因此,我们建议CXCR3-B是预后不良的指标,也可以是化学治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号